newer principles with known drugs and promising new compounds with a more appropriate kinetic or fewer side-effects , deriving from distinct pharmacological groups , as candidates for the treatment of gastrointestinal disorders are considered e.g . anticholinergics ( prifinium or actilonium bromide ) , adrenergic alpha 2-agonists ( clonidine , lidamidine ) for diarrhoea in diabetic neuropathy , adrenergic beta-blockers for shortening postoperative ileus ( propranolol ) , dopamine receptor antagonists ( metoclopramide , domperidone , alizapride ) and another prokinetic substance ( cisapride ) which may be useful for a number of applications as gastro-oesophageal reflux , gastro-paresis , intestinal pseudo-obstruction , cystic fibrosis and constipation , morphine derivatives ( e.g . loperamide ) for intractable diarrhoea and calcium antagonists ( e.g . nifedipine ) for achalasia .
C0072916
cisapride
C0017168
gastro-oesophageal reflux